A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis
Trial details
- Registry ID
- NCT03900429
- Drugs studied
- Liver Biopsy, MGL-3196
TrialRedline tracks 7 clinical trials sponsored by Madrigal Pharmaceuticals, Inc.: 4 Phase 3, 3 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and FibrosisNCT03900429 | Liver Biopsy, MGL-3196 | Active not recruiting | 2028-01Estimated |
| A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)NCT04951219 | Resmetirom | Active not recruiting | 2027-03Estimated |
| A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)NCT05500222 | Resmetirom | Active not recruiting | 2026-12Estimated |
| A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease PatientsNCT04197479 | Resmetirom | Completed | 2023-01-06Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASHNCT07335601 | Resmetirom | Recruiting | 2028-08Estimated |
| Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)NCT03038022 | MGL-3196 (resmetirom) | Completed | 2018-01-15Actual |
| Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH)NCT02912260 | MGL-3196 | Completed | 2017-10-25Actual |
Names as written in the registry records.
NCT05500222 · Madrigal Pharmaceuticals, Inc.
Before: 700 participants (planned). After: 845 participants (planned).
NCT07335601 · Madrigal Pharmaceuticals, Inc.
Before: Jul 2027. After: Aug 2028.
Before: Estimated. After: Actual.
Before: 1000 participants (planned). After: 810 participants (actual).
Before: Mar 2026. After: Mar 2027.
NCT07335601 · Madrigal Pharmaceuticals, Inc.
Before: Active not recruiting. After: Recruiting.
NCT02912260 · Madrigal Pharmaceuticals, Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Change from baseline in hepatic fat fraction assessed by MRI-PDFF. After: Measure: Percent Change From Baseline To Week 12 In Hepatic Fat Fraction Assessed By Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF).
Before: Oct 2017. After: 25 Oct 2017.
Before: Active not recruiting. After: Completed.
NCT03038022 · Madrigal Pharmaceuticals, Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Mean Percentage Change in LDL-C From Baseline To Week 12. After: Measure: Mean Percent Change in LDL-C From Baseline To Week 12.